Cullinan Therapeutics Inc (NASDAQ:CGEM) currently has a daily average trading volume of 536.80K but it saw 469783 shares traded in last market. With a market cap of 762.20M USD, the company’s current market price of $13.09 came rising about 2.51 while comparing to the previous closing price of $12.77. In past 52 weeks, the stock remained buoying in the range of price level as high as $30.19 and as low as $7.64. In the recent trading on the day, stock has struck highest price mark of $12.43 while lowest mark touched by it was $13.11.
Taking a look at 20-day trading activity of Cullinan Therapeutics Inc (CGEM) gives us an average price of $14.59, while its current price level is -56.64% below from 52-week high level whereas it is 71.34% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $15.77 while that of 200 days or SMA-200 reads an average of $18.30. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.80% during that period while stretching the period over a month that increases to 6.74%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 37.45 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the UBS which initiated the stock as “Buy” in its note to investors issued on October 24, 2024, recommending a price target of $30 for it.
Over the week, CGEM’s stock price is moving 4.05% up while it is -22.64% when we observe its performance for the past one month. Year-to-date it is 28.46% up and over the past year, the stock is showing an upside performance of 52.03%.
Currently, Cullinan Therapeutics Inc’s total number of outstanding shares is 42.90M. Company’s return on investment (ROI) stands at -22.82% and return on equity (ROE) at -26.18%. Stock’s beta reads -0.19. Stock has a price to book (P/B) ratio of 1.21. Its return on asset (ROA) is -25.01% on average.
